1-9 of 9
episode of care
Close
Sort by
Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 793.
https://doi.org/10.1182/blood-2019-124364
Published: 2019
Journal Articles

The Impact of Chronic Myeloid Leukemia Therapy Management on the Oncology Care Model

Elias J. Jabbour, MD, Martin F Mendiola, MD MPH, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Jay Lin, PhD MBA, Dinara Makenbaeva, MD MBA
Journal: Blood
Blood (2018) 132 (Supplement 1): 2265.
https://doi.org/10.1182/blood-2018-99-112484
Published: 2018
Journal Articles

Economic Burden of Treatment Episodes in Acute Myeloid Leukemia (AML) Patients in the US: A Retrospective Analysis of a Commercial Payer Database

Bruno C Medeiros, MD, Bhavik J Pandya, PharmD, Chi-Chang Chen, PhD, Eric S. Groves, MD PhD, Cat N. Bui, PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 4694.
https://doi.org/10.1182/blood.V130.Suppl_1.4694.4694
Published: 2017
Journal Articles

Real-World Occurrence of Symptoms and Toxicities and Associated Cost Implications in Acute Myeloid Leukemia (AML) Treatment Episodes: A Retrospective Database Analysis in the US

Bhavik J Pandya, PharmD, Bruno C Medeiros, MD, Chi-Chang Chen, PhD, Samuel Wilson, PhD, Eric S. Groves, MD PhD, Laura Elise Horvath, MD, Rolin L. Wade, RpH, MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 2118.
https://doi.org/10.1182/blood.V130.Suppl_1.2118.2118
Published: 2017
Journal Articles

Differences In Treatment Patterns and Costs Among Diffuse Large B-Cell Lymphoma Patients Treated In The Clinic Vs. The Hospital Outpatient Setting

Carolina Reyes, PhD, Stacey Dacosta Byfield, Laura K. Becker, MS, Art Small, MD
Journal: Blood
Blood (2013) 122 (21): 1751.
https://doi.org/10.1182/blood.V122.21.1751.1751
Published: 2013
Journal Articles

Are There Differences in Patient Characteristics, Treatment Patterns and Costs by Treatment Setting?

Stacey Dacosta Byfield, Carolina Reyes, Ph.D., Laura K Becker, MS, Art Small, MD
Journal: Blood
Blood (2012) 120 (21): 4259.
https://doi.org/10.1182/blood.V120.21.4259.4259
Published: 2012
Journal Articles

Trajectory of Hemoglobin (Hb) in Patients Receiving Erythropoiesis-Stimulating Agents (ESAs) for Anemia Due to Concomitantly Administered Myelosuppressive Chemotherapy (CIA) (2006∼2008).

Jerrold Hill, PhD, Ze Cong, MS, Mphil, Gregory P. Hess, MD, MBA, MSc, Robert Nordyke, PhD
Journal: Blood
Blood (2009) 114 (22): 1399.
https://doi.org/10.1182/blood.V114.22.1399.1399
Published: 2009
Journal Articles

The Impact of Methodological Approach on Cost Findings in Comparison of Epoetin Alfa with Darbepoetin Alfa

Xue Song, Stacey R Long, William D Marder, Sean D Sullivan, Joel Kallich, PhD
Journal: Blood
Blood (2008) 112 (11): 1298.
https://doi.org/10.1182/blood.V112.11.1298.1298
Published: 2008
Journal Articles

Cost Estimates of Managing Grade III and IV Pleural Effusions, Pericardial Effusions, and Non-Variceal Gastrointestinal Hemorrhages in Cancer Patients.

Grant H. Skrepnek, PhD, Jeana L. Skora, PharmD
Journal: Blood
Blood (2006) 108 (11): 5510.
https://doi.org/10.1182/blood.V108.11.5510.5510
Published: 2006